Market Intelligence, Clinical Progress, and High-Purity Reagents for Lectin Pathway Inhibitor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MASP2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Enzyme | MASP2 Full-Length / Catalytic Domain Protein High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. Preserves serine protease activity. |
View MASP2 Products |
| Antigen (WT & S604A Mutant) | MASP2 Recombinant Protein (WT & S604A Catalytic Mutant) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed. |
View MASP2 Products |
| Gene Delivery | MASP2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction in complement pathway assays. |
View MASP2 Products |
| Benchmark Ab | Anti-MASP2 (Sequence of Narsoplimab) Recombinant positive control for binding and inhibition assays. |
View MASP2 Products |
| Validator | MASP2 siRNA Set For knockdown verification and assay specificity checks. |
View MASP2 Products |
| Selectivity Control (MASP1) | MASP1 Recombinant Protein Critical homolog for counter-screening; strictly verified by mass spec (>95% purity). |
View MASP1 Products |
| Related Target – MASP3 | Recombinant MASP3 for lectin pathway specificity profiling. | View MASP3 Products |
| Related Target – C3 | Complement C3 downstream effector; biomarker for lectin pathway blockade. | View C3 Products |
| Related Target – C4 | Downstream substrate for functional activity assays. | View C4 Products |
| Related Target – MBL2 | Mannose-Binding Lectin 2; upstream pattern recognition molecule and patient stratification marker. | View MBL2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| MASP1/MASP3 Cross-reactivity Risk | Homolog Panel (MASP1, MASP3) strictly verified by mass spec; >95% purity. |
| MASP1/MASP2 Selectivity Discrimination | Purified MASP1 & MASP2 homolog proteins strictly verified by mass spec; >95% purity. |
| Lectin Pathway Functional Inhibition | High-purity MASP2 WT and S604A catalytic mutant for mechanistic binding and enzymatic assays. |
| Enzymatic Activity Preservation | HEK293 Expressed (Native Glycosylation), Endotoxin Controlled, Theoretical MW confirmed. |
| Zymogen vs Active Conformation | Both Full-length (pro-enzyme capable) and isolated Catalytic Domain available. |
| Cross-species Preclinical Evaluation | Human/Mouse/Cyno MASP2 ortholog proteins available; Sequence Verified. |
| Lack of Clinical Controls | Clinical Benchmark Antibodies (Narsoplimab biosimilar) included for assay standardization. |
| False Positives & Assay Specificity | MASP2 siRNA and inactive mutant controls included for specificity checks. |
Live MASP2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MASP2 therapeutics is intensifying, with Omeros Corporation leading the monoclonal antibody approach through Narsoplimab. As first-generation lectin pathway inhibitors reach regulatory milestones for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and IgA nephropathy (IgAN), the next wave of R&D is targeting broader complement-mediated diseases (e.g., atypical hemolytic uremic syndrome), exploring oral small-molecule active-site inhibitors, subcutaneous formulations, and highly selective biologics that spare MASP1-driven alternative pathway signaling. The shift from broad complement inhibition to precise lectin pathway targeting is driving demand for high-quality reagents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Omeros (Narsoplimab) | HSCT-TMA, IgA Nephropathy, COVID-19 | High-affinity binding (SPR), Selectivity vs MASP1 (need homolog proteins) |
| Small Molecule Inhibitor | Various (Early-stage/Discovery) | Autoimmune, Ophthalmology, Complement-mediated diseases | Enzymatic activity assay (Need catalytic domain protein); Covalent/IC50 profiling |
| Recombinant Biologic / Peptide | Biotech Suppliers / Preclinical | Research/Assay Development, Chronic Inflammation | Active enzyme validation, Endotoxin control for cell assays, High-concentration stability & SPR/BLI binding |
| Gene Therapy / Cell | Academic/Research | Rare Complement Disorders | Lentivirus for stable MASP2-expressing cell lines |
| siRNA / Antisense | Alnylam | Autoimmune nephritis | Knockdown Validation (Need siRNA controls) |
MASP2 Structural and Genetic Features
MASP2 contains three functional domains: CUB1, an EGF-like calcium-binding domain, and CUB2. Key genetic variants include dbSNP rs61735600, dbSNP rs147270785, and an MASPD mutation of uncertain significance that strongly decreases affinity for MBL2 and FCN2, impacting lectin pathway activation.